Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024)

Ovid Therapeutics filings provide 9 years of Capital Expenditures readings, the most recent being -$26000.0 for Q4 2024.

  • Quarterly Capital Expenditures fell 300.0% to -$26000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$26000.0 through Sep 2025, down 120.16% year-over-year, with the annual reading at $90000.0 for FY2024, 125.0% up from the prior year.
  • Capital Expenditures hit -$26000.0 in Q4 2024 for Ovid Therapeutics, down from $63000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.1 million in Q2 2022 and bottomed at -$834500.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $90178.8, with a median of $24615.0 recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 56040.81% in 2020, while the deepest fall reached 14696.06% in 2020.
  • Ovid Therapeutics' Capital Expenditures stood at $48598.0 in 2020, then tumbled by 112.58% to -$6115.0 in 2021, then skyrocketed by 16012.33% to $973039.0 in 2022, then plummeted by 98.66% to $13000.0 in 2023, then crashed by 300.0% to -$26000.0 in 2024.
  • Per Business Quant, the three most recent readings for OVID's Capital Expenditures are -$26000.0 (Q4 2024), $63000.0 (Q3 2024), and $34000.0 (Q2 2024).